Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R03)

archived

Purpose. Under this Funding Opportunity Announcement (FOA), the National Institute on Alcohol Abuse and Alcoholism requests Research Project Grant (expanded R03) applications to conduct initial studies of the safety and feasibility of pharmacotherapies for alcohol use disorders in HIV-infected populations. These studies will set the stage for future research to: 1) determine the efficacy and effectiveness of innovative single and combined pharmacologic therapies for alcohol use disorders in HIV+ populations for the purpose of improving adherence to antiretroviral medications, reducing the rate of viral mutation and toxicity related to alcohol-ARV interactions, and reducing sexual risk-taking; and 2) assess the potential usefulness of medications for alcohol use disorders in preventing secondary HIV infections in targeted high risk populations of gay men and minority women. Mechanism of Support. This FOA will utilize the expanded R03 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AA-09-007, that solicits applications under the R01 grant mechanism to conduct studies to determine the efficacy and effectiveness of innovative single and combined pharmacologic therapies for alcohol use disorders in HIV+ populations. Projects funded under this announcement shall include pilot and feasibility studies; small, self-contained research projects; and new research collaborations between HIV/AIDS and alcohol researchers. As the R03 is intended to support small research projects that can be carried out in a short period of time with limited resources, it is intended that, with the use of this mechanism, investigators and collaborative research groups will be able to conduct initial pilot and feasibility studies to better position them for a subsequent R01 application. Funds Available and Anticipated Number of Awards. A total of up to $1M will be awarded and 4-6 awards are anticipated.

High